The Trademark Trial and Appeal Board issued the decision after trial sustaining Fross Zelnick’s oppositions to REGENAL and REGENALL (for “pharmaceutical preparations for the treatment of damaged or injured tissue; nutritional supplements”) based on our client Genzyme Corporation’s mark, RENAGEL, registered for “pharmaceuticals, namely, phosphate binders for treatment of hyperphosphatemia.” Hyperphosphatemia is an electrolyte disorder, which results in elevated levels of phosphate in the patient’s blood, usually patients with chronic kidney disease.